The right dose for the right patient

Abstract

Even in the setting of intensive, multiagent chemotherapy treatment, interpatient variability in pharmacokinetics and adequate dosing are keenly important to the successful treatment of acute lymphoblastic leukemia (ALL). In this issue of Blood, Kawedia et al report the findings of their pharmacologic studies of dexamethasone and asparaginase, which highlight the significant impact that interpatient variability in dexamethasone and asparaginase drug exposure has on response to treatment and risk of relapse.